Emergent BioSolutions
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 1.6K
- Market Cap
- -
- Introduction
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle
- Conditions
- Healthy Volunteers
- Interventions
- Biological: Botulism Antitoxin Heptavalent (Equine) Types A-GBiological: Botulism Antitoxin Bivalent (Equine) Types A and B
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 36
- Registration Number
- NCT00636519
- Locations
- ๐บ๐ธ
Dr. Gordon Peterson, Loma Linda, California, United States
๐บ๐ธR. Richard Sloop, M. D., Yakima, Washington, United States
Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum
- Conditions
- Symptoms of Inhalational Anthrax
- Interventions
- Biological: NP-015
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 92
- Registration Number
- NCT00448253
- Locations
- ๐บ๐ธ
MDS Pharma Services, Lincoln, Nebraska, United States
Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses
- Conditions
- Healthy
- Interventions
- Biological: Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 40
- Registration Number
- NCT00360737
- Locations
- ๐บ๐ธ
MDS Pharma Services, Phoenix, Arizona, United States
Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
- Conditions
- Smallpox
- First Posted Date
- 2003-01-31
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 353
- Registration Number
- NCT00053495
- Locations
- ๐บ๐ธ
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
๐บ๐ธPRA International, Lenexa, Kansas, United States
๐บ๐ธMemorial Hospital of Rhode IslandDivision of Infectious Diseases, Pawtucket, Rhode Island, United States
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
- Conditions
- Smallpox
- Interventions
- Biological: ACAM2000 Smallpox Vaccine
- First Posted Date
- 2003-01-31
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 357
- Registration Number
- NCT00053482
- Locations
- ๐บ๐ธ
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
๐บ๐ธPRA International, Lenexa, Kansas, United States
๐บ๐ธMemorial Hospital of Rhode Island Division of Infectious Diseases, Pawtucket, Rhode Island, United States